MLKL-mRNA treatment rapidly induces T cell responses directed against tumor neo-antigens and requires CD4<sup>+</sup> and CD8<sup>+</sup> T cells to prevent tumor growth.
We systematically searched PubMed, Embase, Web of Science and CNKI to obtain all relevant articles about the prognostic value of abnormally expressed MLKL in patients with any type of tumor.
Low expression of mixed lineage kinase domain-like protein was associated with decreased overall survival (74.9 vs 79.8 months; P = .006) and recurrence-free survival (69.6 vs 78.8 months; P = .005) among patients with Tumor Node Metastasis (TNM) stage II colon cancer.